Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 24:4:195.
doi: 10.3389/fonc.2014.00195. eCollection 2014.

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics

Affiliations
Review

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics

Edward Hammond et al. Front Oncol. .

Abstract

Heparan sulfate proteoglycans (HSPGs) are an integral and dynamic part of normal tissue architecture at the cell surface and within the extracellular matrix. The modification of HSPGs in the tumor microenvironment is known to result not just in structural but also functional consequences, which significantly impact cancer progression. As substrates for the key enzymes sulfatases and heparanase, the modification of HSPGs is typically characterized by the degradation of heparan sulfate (HS) chains/sulfation patterns via the endo-6-O-sulfatases (Sulf1 and Sulf2) or by heparanase, an endo-glycosidase that cleaves the HS polymers releasing smaller fragments from HSPG complexes. Numerous studies have demonstrated how these enzymes actively influence cancer cell proliferation, signaling, invasion, and metastasis. The activity or expression of these enzymes has been reported to be modified in a variety of cancers. Such observations are consistent with the degradation of normal architecture and basement membranes, which are typically compromised in metastatic disease. Moreover, recent studies elucidating the requirements for these proteins in tumor initiation and progression exemplify their importance in the development and progression of cancer. Thus, as the influence of the tumor microenvironment in cancer progression becomes more apparent, the focus on targeting enzymes that degrade HSPGs highlights one approach to maintain normal tissue architecture, inhibit tumor progression, and block metastasis. This review discusses the role of these enzymes in the context of the tumor microenvironment and their promise as therapeutic targets for the treatment of cancer.

Keywords: Sulf1; Sulf2; cancer therapy; heparan sulfate; heparanase; tumor microenvironment targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms whereby heparanase, Sulf1, and Sulf2 regulate HS function to promote or inhibit tumor growth and spread. (A) HS modification by these three enzymes can have promoting or inhibiting effects on growth factor (GF) signaling. (B) Heparanase, in association with sheddases, can stimulate HSPG shedding, dispersing autocrine to paracrine signaling. (C) Heparanase and Sulf2 can up-regulate HSPG expression to promote GF signaling. And (D) heparanase can induce exosome secretion allowing tumor cell communication with neighboring cells.

References

    1. Kim S-H, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol (2011) 209:139–5110.1530/JOE-10-0377 - DOI - PubMed
    1. Szatmári T, Dobra K. The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol (2013) 3:310.10.3389/fonc.2013.00310 - DOI - PMC - PubMed
    1. Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD, Karamanos NK. Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol (2014) 4:4.10.3389/fonc.2014.00004 - DOI - PMC - PubMed
    1. Gomes AM, Stelling MP, Pavão MSG. Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed Res Int (2013) 2013:852093.10.1155/2013/852093 - DOI - PMC - PubMed
    1. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL-S, et al. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 280:2294–30610.1111/febs.12168 - DOI - PMC - PubMed